Actively Recruiting
Phase 3 Trial Comparing Tenecteplase and Alteplase with Mechanical Thrombectomy for Acute Large Vessel Occlusive Stroke
Led by Xuanwu Hospital, Beijing · Updated on 2026-04-09
850
Participants Needed
1
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating two clot-dissolving drugs for treating acute large vessel occlusion stroke when given within 4.5 hours from symptom onset. This phase III, multicenter, randomized clinical trial compares intravenous tenecteplase followed by mechanical thrombectomy to intravenous alteplase followed by mechanical thrombectomy. The purpose is to assess and compare the effectiveness and safety of these two thrombolytic agents in improving stroke outcomes. Participants will be randomly assigned to one of two treatment groups. One group receives a single rapid intravenous bolus of tenecteplase 0.25 mgkg, max 25 mg before the mechanical thrombectomy procedure. The other group receives intravenous alteplase 0.9 mgkg, max 90 mg given as a 10% bolus followed by a 90% infusion over one hour before the thrombectomy. Both treatments are followed by the mechanical clot removal procedure. During the study, participants will be followed for 90 days after randomization. Researchers will evaluate functional independence using the modified Rankin Score and other measures such as blood flow restoration on imaging, neurological status, and daily living activities. Safety and treatment effectiveness will be monitored through clinical assessments and imaging at various time points. The total participation time includes initial treatment and follow-up evaluations up to 90 days.
CONDITIONS
Brief Title
Efficacy and Safety of Tenecteplase Bridging Mechanical Thrombectomy for Acute Large Vessel Occlusion Stroke
Research Team
L
Lu Wang, MD
X
Xiuhai Guo, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here